Biotech News

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics (RANI)Rani Therapeutics2025-11-06 21:30 ESTEarnings

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – –

Rani Therapeutics

Rani Therapeutics is a drug-delivery company focused on oral delivery of biologics and other therapeutics. Its platform aims to replace injections with swallowable delivery.

Recent company news

RANIRani Therapeutics2026-08-04 12:00 EST

Rani Therapeutics Appoints Michelle Gilson to Board of Directors

RANIRani Therapeutics2026-07-20 20:05 EST

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RANIRani Therapeutics2026-07-15 12:00 EST

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

RANIRani Therapeutics2026-07-09 20:05 EST

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

RANIRani Therapeutics2026-06-29 12:00 EST

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

Stock data

Close: 0.78 USD
Market cap: 96.4M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States